Litcius/Paper detail

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N. Sternberg, Johann S. de Bono, Daniel Castellano, Bertrand Tombal, Christian Wülfing, Michael Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Stéphane Oudard, Gaetano Facchini, Elizabeth M. Poole, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Samira Bensfia, Ronald de Wit

2020The Lancet Oncology66 citationsDOIOpen Access PDF

Topics & Concepts

CabazitaxelEnzalutamideMedicineProstate cancerDocetaxelOncologyInternal medicineClinical endpointPopulationAndrogen deprivation therapyAbiraterone acetateQuality of life (healthcare)Progression-free survivalClinical trialCancerAndrogen receptorChemotherapyEnvironmental healthNursingProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments